top of page
Imbruvica (ibrutinib) is a medication used to treat certain cancers in adults, including: Mantle cell lymphoma (MCL), Chronic lymphocytic leukemia (CLL)/Small lymphocytic leukemia (SLL), Waldenström’s macroglobulinemia (WM), Marginal zone lymphoma (MZL) It's also used to treat chronic graft versus host disease (cGVHD) in adult and pediatric patients who are at least one years old. Imbruvica is available in the following dosage forms and strengths: 70 mg and 140 mg oral capsules, 140 mg, 280 mg, 420 mg, and 560 mg oral tablets, 70 mg/mL oral suspension Imbruvica is not right for everyone. Discuss treatment options with your doctor that may be best for you. Fact Table Formula C25H24N6O2 License US FDA, US DailyMed, EU EMA Bioavailability Less than 4% Legal status Rx-Only Chemical Name Ibrutinib Elimination half-life 4–6 hours Dosage (Strength) 140mg Pregnancy Not Recommended Brands Imbruvica Protein binding 97.3% PubChem CID 24821094 MedlinePlus a614007 ChEBI 76612 ATC code L01EL01 DrugBank DB09053 KEGG D10223 Routes of administration By mouth

Imbruvica (Ibrutinib)

  • Each patient's dose depends on the condition being treated. You should follow your doctor's instructions on taking Imbruvica. If you have any questions or concerns, talk to your doctor or pharmacist. Recommended dose forMCL and MZL: 560 mg by mouth once daily Recommended dose forCLL/SLL and WM: 420 mg by mouth once daily Recommended dose forcGVHD in patients who are least 12 years old: 420 mg by mouth once daily Recommended dose forcGVHD in patients 1 to 11 years of age: 240 mg/m2 by mouth once daily (up to a maximum dose of 420 mg) Patients with liver problems may require a dose adjustment.
bottom of page